business

UniQure Shares Soar After FDA Reversal on Its Huntington’s Therapy

Bloomberg Markets · Jun 17, 2026, 11:27 AM · Also reported by 2 other sources

UniQure NV shares soared after the company announced it will be able to seek US approval for its Huntington’s disease gene therapy before conducting a new study, a dramatic reversal that shows the Trump administration is relaxing its previous hard-line stance on drug reviews.

Read full story on Bloomberg Markets → More top stories

Also covered by

CNBC UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency STAT News STAT+: Following dispute with FDA, UniQure is cleared to submit Huntington’s treatment for approval

Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

UniQure Shares Soar After FDA Reversal on Its Huntington’s Therapy

Also covered by

More in business